NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
Amgen
University of Maryland, Baltimore
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Emory University
M.D. Anderson Cancer Center
AstraZeneca
MedImmune LLC